"ADVANCEMENTS IN ANALYTICAL METHODOLOGIES FOR THE DETERMINATION OF BUMETANIDE IN COMBINED DOSAGE FORMS"
Main Article Content
Keywords
Bumetanide, Furosemide, Loop diuretics, Analytical Methods (HPLC, LC-MS/MS), Combined Dosage-Form
Abstract
Bumetanide, a potent loop diuretic, is used in managing edema in congestive heart failure, renal impairment, and hepatic cirhosis. It has also been linked to neurological disorders, increasing the need for reliable analytical methods. Accurate determination of Bumetanide in combined dosage forms is crucial for quality, safety, and efficacy. Challenges include matrix complexity, interference from co-formulated drugs, and stability issues. Advancements in analytical methodologies have improved resolution, accuracy, and faster analysis. Hyphenated techniques like LC-MS/MS have enhanced sensitivity and specificity. Green analytical approaches and Quality by Design principles promote eco-friendly practices. Future perspectives emphasize the need for innovative, automated, and environmentally conscious methodologies for bumetanide determination in combined dosage forms.
References
2. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Annals of internal medicine. 1991 May 15;114(10):886-94.
3. Brater DC. Clinical pharmacology of loop diuretics. Drugs. 1991 Jun;41(Suppl 3):14-22.
4. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 2471, Bumetanide; 2025 Sept. 12.
5. Huang X, Dorhout Mees E, Vos P, Hamza S, Braam B. Everything we always wanted to know about furosemide but were afraid to ask. American Journal of Physiology-Renal Physiology. 2016 May 1;310(10): F958-71.
6. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 3440, Furosemide; 2025 Sept. 12.
7. Hedaya MA. Bumetanide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
8. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387-95.
9. Lytle C, Xu JC, Biemesderfer D, Forbush B 3rd. Distribution and diversity of Na-K-Cl cotransport proteins: a study with monoclonal antibodies. Am J Physiol. 1995;269(6 Pt 1):C1496-505.
10. Kramp RA, DiPette DJ, Gavras H. Clinical pharmacology of bumetanide. Clin Pharmacol Ther. 1982;32(2):221-7.
11. Lant AF, Wilson GM. A comparison of bumetanide and furosemide. Br Med J. 1970;4(5734):331-3.
12. Russell JM. Sodium-potassium-chloride cotransport. Physiol Rev. 2000;80(1):211-76.
13. Lemonnier E, et al. Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. Transl Psychiatry. 2012;2(12): e202.
14. Löscher W, Kaila K. CNS pharmacology of bumetanide: from epilepsy to autism. Pharmacol Ther. 2022; 230:107963.
15. Hedaya MA. Bumetanide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2025 Sep 13].
16. Brater DC. Diuretic therapy. N Engl J Med. 1998 Aug 6;339(6):387-95.
17. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition.
18. Brunton ll. Goodman & Gilman’s manual of pharmacology and Therapeutics, 2nd Edition
19. Sweetman SC (ed). Martindale: The Complete Drug Reference, Pharmaceutical Press.
20. Katzung BG. Basic & Clinical Pharmacology, 15th Edition.
21. Mullens W, et al. Diuretic therapy in heart failure: current approaches and practical considerations. J Am Coll Cardiol. 2020;75(3):233 245
22. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387
23. Hedaya MA. Bumetanide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
24. Choudhary P, Kumar A. Analytical methods for loop diuretics: Bumetanide. J Anal Pharm Res. 2016;5(1):1 8.
25. Bao-qiang R. “Determination of Bumetanide tablets by HPLC”. Strait Pharmaceutical Journal 1 (2006): 77-78.
26. Dong-ming P., et al. “Determination of Bumetanide for injection by HPLC”. Chinese Journal of Modern Applied Pharmacy 5(2006):404-406
27. Sanz NV., et al. “Determination and characterization of diuretics in human urine by liquid chromatography coupled to pneumatically assisted electrospray ionization mass spectrometry”. Journal of Mass Spectrometry 36.6 (2001): 1-18.
28. Deventer K., et al. “Simultaneous determination of beta-blocking agents and diuretics in doping analysis by liquid chromatography/mass spectrometry with scan-to-scan polarity switching”. Rapid Communication in Mass Spectrometry 19(2005): 90-98.
29. Seethi R., et al. “Development and validation of RP-HPLC for estimation of Bumetanide in tablet formulation”. Indian Journal of Field Veterinarians 9.4 (2014): 46-53.
30. indian Pharmacopoeia Commission. Indian Pharmacopoeia 2018 – Furosemide monograph.
31. British Pharmacopoeia Commission. British Pharmacopoeia Online – Furosemide monograph.
32. European Directorate for the Quality of Medicines. European Pharmacopoeia 10.0. Furosemide monograph.
33. United States Pharmacopeia (USP 44–NF 39). Furosemide monograph.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dhrumi Y Patel
Department of Pharmaceutical Quality Assurance, Khyati College of Pharmacy, Ahmedabad, Gujarat, India.
Dr. Neha Tiwari
Department of Pharmaceutical Chemistry, Khyati College of Pharmacy, Ahmedabad, Gujarat, India.
Dr. Pragnesh Patani
Department of Pharmacology, Khyati College of Pharmacy, Ahmedabad, Gujarat, India.